Breast cancer insights: Significance of Murraya koenigii and their potential in prevention and therapeutic intervention

The review aims at discussing the therapeutic potential of Murrayanine, a bioactive compound obtained by using
Murraya koenigii, as a new strategy in the prevention and treatment of breast cancer. Due to the prevalence of
breast cancer across the world and the constraints of traditional treatment methods, this review examines the
multiple mechanisms of action of Murrayanine, such as inducing apoptosis and inhibiting cell growth, as well as
altering major signalling pathways, such as PI3K/Akt, NF-kB, and MAPK. There is support of evidence regarding
preclinical studies, which indicate that Murrayanine has strong anticancer activity in that it is effective against a
range of cancer cell types, such as breast, colon, and lung cancer. It has been demonstrated to overcome
multidrug resistance and minimise the levels of chemotherapy induced cytotoxicity to normal cells, thereby
increasing the therapeutic efficacy of conventional chemotherapy agents, doxorubicin and paclitaxel. In addition,
Murrayanine as an antioxidant and anti-inflammatory agent also adds to its protective effects by preventing
oxidative stress and inflammation associated with cancer progression. The main conclusions indicate the synergistic
value of Murrayanine with chemotherapy that can be used to enhance the treatment process, decrease
the adverse effects. Nevertheless, its issues like low bioavailability and the necessity to engage more clinical
validation should be resolved to make the full translation of Murrayanine to clinical practise possible. The review
recommends further investigation of the role of Murrayanine in the integrative cancer therapy.